Literature DB >> 1689735

Characterization of insulin-like growth factor-binding proteins in human serum from patients with chronic renal failure.

F Liu1, D R Powell, R L Hintz.   

Abstract

Western ligand blotting of human serum reveals proteins of 41.5, 38, 33, 28, and 23 kD which will specifically bind [125I]insulin-like growth factor-I [( 125I]IGF-I). The relationship of these binding proteins (BPs) to the two serum BP-IGF complexes of 150 and 40 kD and their relationship to the two purified and well characterized IGF-BPs, BP-25 and BP-53, are not clear. The studies reported here used gel filtration, Western ligand blotting, deglycosylation, affinity cross-linking, and immunoprecipitation with antisera against BP-25 and BP-53 to explore the relationship among these IGF-BP forms. Serum from children with chronic renal failure was used for this study, since, by Western ligand blot, it was rich in all five IGF-BPs. The 28- and 33-kD BPs, which were hard to detect in normal serum, were elevated in chronic renal failure serum. Using this serum in each experiment, it was found that the large (150-kD) BP-IGF complex contained only the 41.5- and 38-kD BPs. Both of these BPs were precipitated by anti-BP-53 antiserum, but not by anti-BP-25 antisera, and both BPs were deglycosylated by endoglycosidase-F to a single 31-kD protein which retained the ability to bind IGF-I. This molecular mass of 31 kD is similar to the 28.7-kD mass for nonglycosylated BP-53 predicted by cDNA sequence analysis. In contrast, the 33-, 28-, and 23-kD BPs were only detected in the small (40-kD) BP-IGF complex. None of the three BPs was precipitated by anti-BP-53 antiserum, and none was digested by endoglycosidase-F. The 28-kD BP comigrated with pure BP-25 under all conditions and was precipitated by two independent anti-BP-25 antisera. The 33-kD BP was also precipitated by both anti-BP-25 antisera, while the 23-kD BP was not precipitated by any of the antisera tested. Thus, BP-53 consists of a core protein of 28.7 kD which is differentially glycosylated in serum to form two BPs of 41.5 and 38 kD; these BPs circulate exclusively as part of the large BP-IGF complex. BP-25 circulates in the small BP-IGF complex as a nonglycosylated protein with an apparent mol wt of 28 kD.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689735     DOI: 10.1210/jcem-70-3-620

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Disturbance of growth hormone--insulin-like growth factor axis in uraemia. Implications for recombinant human growth hormone treatment.

Authors:  B Tönshoff; F Schaefer; O Mehls
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

2.  Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia.

Authors:  W F Blum; M B Ranke; K Kietzmann; B Tönshoff; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

3.  Altered affinity of insulin-like growth factor II (IGF-II) for receptors and IGF-binding proteins, resulting from limited modifications of the IGF-II molecule.

Authors:  Y Oh; M W Beukers; H M Pham; P A Smanik; M C Smith; R G Rosenfeld
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

4.  Abnormal serum IGF-II transport in non-islet cell tumor hypoglycemia results from abnormalities of both IGF binding protein-3 and acid labile subunit and leads to elevation of serum free IGF-II.

Authors:  W H Daughaday; B Trivedi; R C Baxter
Journal:  Endocrine       Date:  1995-06       Impact factor: 3.633

Review 5.  Growth hormone/insulin-like growth factor system in children with chronic renal failure.

Authors:  Burkhard Tönshoff; Daniela Kiepe; Sonia Ciarmatori
Journal:  Pediatr Nephrol       Date:  2005-02-04       Impact factor: 3.714

6.  Insulin-like growth factor binding protein-3 protease activity in the urine of children with chronic renal failure.

Authors:  D Y Lee; P Cohen; A M Krensky; R G Rosenfeld; P D Yorgin
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

7.  Insulin-like growth factor-1, growth hormone-dependent insulin-like growth factor-binding protein and growth in children with chronic renal failure.

Authors:  E M Hodson; A S Brown; L P Roy; A R Rosenberg
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

Review 8.  Insulin-like growth factor binding proteins as growth inhibitors in children with chronic renal failure.

Authors:  D R Powell; F Liu; B K Baker; P D Lee; R L Hintz
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

9.  Serum insulin-like growth factors and their binding proteins in children with end-stage renal disease.

Authors:  B Tönshoff; W F Blum; O Mehls
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

10.  Differential effects of thermal injury on circulating insulin-like growth factor binding proteins in burn patients.

Authors:  A Ghahary; S Fu; Y J Shen; H A Shankowsky; E E Tredget
Journal:  Mol Cell Biochem       Date:  1994-06-29       Impact factor: 3.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.